Refine
Has Fulltext
- yes (11)
Is part of the Bibliography
- yes (11)
Document Type
- Journal article (11)
Language
- English (11)
Keywords
- multiple myeloma (5)
- CXCR4 (4)
- PET (3)
- medicine (3)
- molecular imaging (3)
- positron emission tomography (3)
- theranostics (3)
- FDG (2)
- PRRT (2)
- bone disease (2)
Institute
- Klinik und Poliklinik für Nuklearmedizin (10)
- Medizinische Klinik und Poliklinik II (5)
- Pathologisches Institut (3)
- Abteilung für Molekulare Innere Medizin (in der Medizinischen Klinik und Poliklinik II) (2)
- Institut für Klinische Biochemie und Pathobiochemie (1)
- Institut für Klinische Epidemiologie und Biometrie (1)
- Institut für Medizinische Strahlenkunde und Zellforschung (1)
- Medizinische Klinik und Poliklinik I (1)
- Neurochirurgische Klinik und Poliklinik (1)
Sonstige beteiligte Institutionen
The aim of this study was to investigate the prognostic value of 18F-fluoro-deoxyglucose positron emission tomography–computed tomography (18F-FDG-PET/CT) in 37 patients with a history of multiple myeloma (MM) and suspected or confirmed recurrence after stem cell transplantation (SCT). All patients had been heavily pre-treated. Time to progression (TTP) and overall survival (OS) were correlated to a number of different PET-derived as well as clinical parameters. Impact on patient management was assessed.
Absence of FDG-avid MM foci was a positive prognostic factor for both TTP and OS (p<0.01). Presence of >10 focal lesions correlated with both TTP (p<0.01) and OS (p<0.05). Interestingly, presence of >10 lesions in the appendicular skeleton proved to have the strongest association with disease progression. Intensity of glucose uptake and presence of extramedullary disease were associated with shorter TTP (p=0.037 and p=0.049, respectively). Manifestations in soft tissue structures turned out to be a strong negative predictor for both, TTP and OS (p<0.01, respectively). PET resulted in a change of management in 30% of patients.
Our data underline the prognostic value of 18F-FDG-PET/CT in MM patients also in the setting of post-SCT relapse. PET/CT has a significant impact on patient management.